Collaborations
Biotie currently has commercial collaborations with Lundbeck, UCB Pharma, Roche and Seikagaku Corp.
We seek to enter partnerships for products where collaboration adds expertise and additional resources, particularly for those products where specialist expertise is required or that target markets with a large, primary care component such as our VAP-1 antibody for inflammatory disease and our small-molecule PDE4 inhibitor, ronomilast, for chronic obstructive pulmonary disease (COPD).
| Lundbeck |
Nalmefene |
World-wide |
Alcohol dependence |
License agreement, up to €84 million
in milestones, plus royalties on sales |
| UCB |
SYN115
|
World wide |
Parkinson´s disease |
License agreement, up to $360M in regulatory and commercial milestones, plus royalties on sales |
| Roche |
SYN120 |
|
Alzheimer´s disease |
Buy-back right at a pre-specified milestone |
| Seikagaku Corp |
VAP-1 antibody |
Japan, Taiwan, Singapore,
New Zealand, Australia |
Inflammatory disorders |
$16.7 MM license agree-
ment; eligible for royalties
on future sales |
|
VAP-1 SSAO |
Japan, Taiwan, Singapore,
New Zealand, Australia |
Inflammatory disorders |
Option agreement for up
to $16.7 MM license agree-
ment; eligible for royalties
on future sales |
   
------
Updated December 9, 2011
|